[go: up one dir, main page]

WO2012104589A1 - Troubles liés au poids - Google Patents

Troubles liés au poids Download PDF

Info

Publication number
WO2012104589A1
WO2012104589A1 PCT/GB2012/000108 GB2012000108W WO2012104589A1 WO 2012104589 A1 WO2012104589 A1 WO 2012104589A1 GB 2012000108 W GB2012000108 W GB 2012000108W WO 2012104589 A1 WO2012104589 A1 WO 2012104589A1
Authority
WO
WIPO (PCT)
Prior art keywords
tst
compound
expression
activity
weight related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2012/000108
Other languages
English (en)
Inventor
Nicholas M. Morton
Scott Webster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh filed Critical University of Edinburgh
Publication of WO2012104589A1 publication Critical patent/WO2012104589A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention provides compounds for the treatment or prevention of weight related disorders as well as methods for diagnosing or detecting incidences of weight related disorders and/or a susceptibility and/or predisposition thereto.
  • US Patent No 5,601,806 discloses the use of thiotaurine and its analogues as an antioxidant for skin lesions (as occurring in, for example, sunburn). In this patent the authors also describe the use of an alloxan diabetes model in order to determine the effects of thiotaurine administration on alloxan-induced diabetes. The patent discloses that thiotaurine suppresses the increase in triglycerides and blood sugar in this model of diabetes. US Patent No 5,601,806 does not disclose the mode of action of thiotaurine or any link between the compound, thiotaurine, and the treatment or prevention of weight related disorders.
  • the present invention aims to provide new and effective treatments for weight related disorders.
  • the present invention is based on the finding that expression of the gene encoding the enzyme, thiosulfate sulphur transferase (TsT: the gene being referred to hereinafter as the TsT gene) and the activity or function of the TsT enzyme itself, is elevated in the tissues of lean animals. Consequently, the invention provides compositions, methods and medicaments for treating or preventing weight related disorders as well as methods and assays for diagnosing or detecting a weight related disorder and/or a predisposition/susceptibility thereto.
  • TsT thiosulfate sulphur transferase
  • TsT encompasses (as appropriate) both the enzyme, thiosulfate sulphur transferase and the gene (TsT) encoding the same.
  • a first aspect of this invention provides compounds which modulate TsT activity, function and/or expression for use in treating or preventing weight related disorders.
  • the invention provides use of compounds which modulate thiosulfate sulphur transferase TsT activity, function and/or expression for the manufacture of a medicament for treating or preventing weight related disorders.
  • the invention in a third aspect, relates to a method of treating a weight related disorder, said method comprising the steps of administering to a subject in need thereof, a therapeutically effective amount of a compound which modulates TsT activity, function and/or expression.
  • a subject in need thereof encompasses subjects suffering or convalescing from a weight related disorder as well as those predisposed or susceptible to, one or more of the weight related disorders described herein.
  • the phrase "compounds which modulate” should be understood as encompassing compounds which either increase or decrease the expression, function and/Or activity of TsT.
  • the compounds which modulate TsT activity function and/or expression comprise compounds which specifically increase, augment or enhance the activity function and/or expression of the TsT enzyme or the gene (TsT) encoding the same.
  • TsT activity, function and/or expression may be evaluated or determined by reference to, or comparison with, a control system exhibiting normal or wild-type TsT/TsT function, expression and/or activity.
  • compounds may encompass small organic/inorganic compounds, lipids, nucleic acids (RNA and/or DNA), carbohydrates, proteins (including peptides, polypeptides and/or amino acids), antibodies (or fragments (for example Fab or Fab 2 fragments) or antigen binding fragments, thereof) - including monoclonal and/or polyclonal antibodies.
  • the compounds may comprise agonists or antagonists of TsT activity, function and/or expression.
  • the compounds provided by this invention may be designed to specifically inhibit, reduce or antagonise TsT expression, function and/or activity.
  • compounds provided by this invention may comprise antisense, silencing and/or interfering nucleic acids.
  • antisense nucleic acids known as antisense oligonucleotides
  • antisense oligonucleotides may comprise DNA or RNA and may comprise sequences complementary to mRNA sequences encoding the TsT enzyme or compounds associated with TsT function, activity and/or expression.
  • RNA molecules which may be used to modulate the function, activity and/or expression of the fsf gene or sequences encoding compounds associated with TsT function, activity and/or expression.
  • silencing and/or small interfering (si) RNA molecules which may be used to modulate the function, activity and/or expression of the fsf gene or sequences encoding compounds associated with TsT function, activity and/or expression.
  • BIOPREDi and/or siDesign center By analysing wild type TsT gene sequences and with the aid of algorithms such as BIOPREDi and/or siDesign center, one of skill could readily determine or computationally predict oligonucleotide sequences that have an optimal knock-down effect for these genes (see for example: http://www.dharmacon.com/DesignCenter/DesignCenterPage.aspx).
  • the skilled person may generate and test an array or library of different oligonucleotides to determine whether or not they are capable of modulating the expression, function and/or activity of the Ts
  • compounds which antagonise TsT function, expression and/or activity may include antibodies which exhibit specificity, selectivity and/or affinity for an epitope of TsT - wherein binding to said epitope results in reduced TsT expression, function and/or activity - perhaps through blocking of the active site of the TsT enzyme.
  • the invention relates to compounds which agonise, activate or increase/enhance TsT expression, function and/or activity.
  • Compounds of this type may be referred to as "TsT activators” and may find particular application in the treatment of diseases and/or conditions/disorders which result from reduced TsT expression, function or activity.
  • TsT activator compounds may exert their effects through modulation of sulfur flux.
  • the term "TsT modulator” or “TsT activator” may include compounds which allosterically modulate TsT activity (possibly via modulation of sulfur flux).
  • TsT enzyme itself may be used to treat or prevent conditions which occur as a result of reduced TsT expression, function and/or activity - the TsT enzyme being prepared or purified from samples comprising TsT or produced using recombinant technology and associated affinity purification means.
  • TsT agonists may further include TsT enzyme substrates or analogues thereof, wherein said agonists increase the function, activity and/or expression of the TsT enzyme.
  • Examples of compounds which increase the function and/or activity of the TsT enzyme and/or TsT gene include compounds comprising thiosulfate, for example sodium thiosulfate (Na2S 2 03).
  • thiosulfate for example sodium thiosulfate (Na2S 2 03).
  • any suitable cation modification to a thiosulfate compound may find utility and the invention encompasses pharmaceutically acceptable salts, hydrates, derivatives and/or variants of thiosulfate.
  • Such variants may include tetrathionate (S 4 O 2" ) or other polythionates ([S n (S03) 2 ] 2" where n is two or more).
  • the invention provides thiosulfate, or a variant or derivative thereof as described herein, for use in treating or preventing weight associated disorders.
  • the invention provides use of thiosulfate, or a variant or derivative thereof as described herein, for the manufacture of a medicament for the treatment and/or prevention of weight related disorders.
  • a yet further embodiment provides a method of treating or preventing a weight related disorder, said method comprising administering a therapeutically ef fective amount of thiosulfate, or a variant or derivative thereof as described herein, to a subject in need thereof.
  • compounds of this invention having utility in the treatment of weight related disorders may include those having two directly bonded sulfur atoms thus: Si-S 2 , such as the thiosulphate compounds and derivatives mentioned above.
  • Sj may have substituents such as one or more oxygens as in thiosulfate, and/or Si may have organic substituents such as in the compounds of formula I as discussed below.
  • S 2 may be bonded to H, may form a salt with a cation or cations or may be bonded to another atom or group.
  • a compound may take the form of a dimer with two Si-S 2 groups bonded together (Si-S2-Sr-S2>)-
  • Such dimeric species might not directly modulate the function and/or activity of TST, however they may be considered to be pro-drug compounds that are metabolised in vivo to form compounds having the S1-S2 feature and which modulate the function and/or activity of TST.
  • Examples of compounds of this invention having utility in the treatment of weight related disorders may include those of the general formula I:
  • Y is a hydrocarbyl radical which may be substituted or unsubstituted, saturated or unsaturated, for example alkyl, alkenyl, alkynyl or aryl;
  • T is a C]-2 hydrocarbyl linking group or may be absent;
  • — is an optional bond
  • Z is sulfur and may form a bond with hydrogen (S-H), or a salt with a cation, for example with a monovalent metal such as lithium (S-Li), sodium (S-Na) or potassium (S-K).
  • TrrrrM Z ma y a j so ex j st j n a dimeric form ⁇ — " z M—S— S— ⁇ — Y (or ( ⁇ — "ErrrM— ) ⁇
  • Y, T and M may be the same or different for each occurrence and the optional bond— may be present or absent for each occurrence.
  • TrrrrM Z m ⁇ which modulate the function and or activity of TST.
  • alkyl is meant herein a saturated hydrocarbyl radical, which may be straight-chain, cyclic or branched.
  • a carbon-carbon double bond provides an alkenyl group; the presence of a carbon-carbon triple bond provides an alkynyl group.
  • alkenyl and alkynyl groups may be straight-chain, cyclic or branched.
  • alkyl, alkenyl and alkynyl groups Y will comprise from 1 to 25 carbon atoms, more usually 1 to 10 carbon atoms, more usually still 1 to 6 carbon atoms or even 1 to 4 carbon atoms.
  • alkenyl and alkynyl groups are 2 carbon atoms and in cycloalkyl groups, 3 carbon atoms.
  • aryl groups Y will comprise a ring or rings (that may be fused) of from 3 to 10 carbons that may include heteroatoms in the ring such as ⁇ , ⁇ or S. Groups Y may be substituted in more than one position.
  • substituents may be (independently for each occurrence) selected from the group consisting of -C0 2 H, -CN, -CON3 ⁇ 4, -CONHR x , -CONR x 2 , halogen (-F, CI , Br or I; in particular_-F), -CF 3f -OH, -OR x , -OCFj , NH 2 , -NHR X , -NR X 2 , - NHCOR , and -NR x COR ; wherein R x is hydrocarbyl, such as alkyl as defined above, for example. In particular R may be C1 alkyl.
  • Y is aryl it may be substituted with one or more substituents (independently for each occurrence) selected from the group consisting of -R x - C3 ⁇ 4OH, -CO2H, halogen ( -F, -CI, -Br, or -I ), CF 3 , -OH, -OR , -OCF3, -N3 ⁇ 4, -NHR X , -NR 2, -NO2, NHCOR x , NR COR x , and -CN; wherein R is hydrocarbyl, such as alkyl as defined above, for example.
  • R x may be CM alkyl.
  • Y is aryl it may be phenyl or substituted phenyl.
  • Y is heteroaryl it may be a five or six membered ring including one or more heteroatoms each independently selected from N, S and O. Examples of heteroaryl Y include substituted or unsubstituted pyridyl or pyrimidyl.
  • the invention may extend to uses, medicaments and methods comprising one or more of the compounds provided in Tables 1-12 below.
  • the invention may also extend to uses, medicaments and methods employing a salt or a dimer (as discussed above) of these compounds.
  • the invention may even extend to uses, medicaments and methods employing two different examples of these compounds coupled together by an S-S linkage i.e. a dimer with different substituents to either side of the S-S linkage.
  • compositions may be formulated as compositions to be administered for the treatment and/or prevention of weight related disorders.
  • Such compositions may take the form of (sterile) pharmaceutical compositions comprising, for example, the compounds of the fourth aspect of this invention together with a pharmaceutically acceptable diluent, excipient or carrier.
  • compositions comprising one or more compounds selected from those described herein in association with, a pharmaceutically acceptable excipient, carrier or diluent.
  • the pharmaceutical compositions do not comprise the compounds disclosed in Table 1-12.
  • compositions include those suitable for oral, topical (including dermal, buccal and sublingual), rectal or parenteral (including subcutaneous, intradermal, intramuscular and intravenous), transdermal, nasal and pulmonary (for example by inhalation) administration.
  • the formulation may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. Methods typically include the step of bringing into association an active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Pharmaceutical formulations suitable for oral administration wherein the carrier is a solid are most preferably presented as unit dose formulations such as boluses, capsules or tablets each containing a predetermined amount of active compound.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine an active compound in a free-flowing form such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, lubricating agent, surface-active agent or dispersing agent.
  • Moulded tablets may be made by moulding an active compound with an inert liquid diluent. Tablets may be optionally coated and, if uncoated, may optionally be scored.
  • Capsules may be prepared by filling an active compound, either alone or in admixture with one or more accessory ingredients, into the capsule shells and then sealing them in the usual manner.
  • Cachets are analogous to capsules wherein an active compound together with any accessory ingredient(s) is sealed in a rice paper envelope.
  • An active compound may also be formulated as dispersible granules, which may for example be suspended in water before administration, or sprinkled on food. The granules may be packaged, e.g., in a sachet.
  • Formulations suitable for oral administration wherein the carrier is a liquid may be presented as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water liquid emulsion.
  • Formulations for oral administration include controlled release dosage forms, e.g., tablets wherein an active compound is formulated in an appropriate release-controlling matrix, or is coated with a suitable release-controlling film. Such formulations may be particularly convenient for prophylactic use.
  • compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
  • Suitable carriers include cocoa butter and other materials commonly used in the art.
  • the suppositories may be conveniently formed by admixture of an active compound with the softened or melted carrier(s) followed by chilling and shaping in moulds.
  • compositions suitable for parenteral administration include sterile solutions or suspensions of an active compound in aqueous or oleaginous vehicles.
  • Injectable preparations may be adapted for bolus injection or continuous infusion. Such preparations are conveniently presented in unit dose or multi-dose containers, which are sealed after introduction of the formulation until required for use.
  • an active compound may be in powder form that is constituted with a suitable vehicle, such as sterile, pyrogen-free water, before use.
  • An active compound may also be formulated as long-acting depot preparations, which may be administered by intramuscular injection or by implantation, e.g., subcutaneously or intramuscularly.
  • Depot preparations may include, for example, suitable polymeric or hydrophobic materials, or ion-exchange resins. Such long-acting formulations are particularly convenient for prophylactic use.
  • Formulations suitable for pulmonary administration via the buccal cavity are presented such that particles containing an active compound and desirably having a diameter in the range of 0.5 to 7 microns are delivered in the bronchial tree of the recipient.
  • such formulations are in the form of finely comminuted powders which may conveniently be presented either in a pierceable capsule, suitably of, for example, gelatin, for use in an inhalation device, or alternatively as a self- propelling formulation comprising an active compound, a suitable liquid or gaseous propellant and optionally other ingredients such as a surfactant and/or a solid diluent.
  • suitable liquid propellants include propane and the chlorofluorocarbons
  • suitable gaseous propellants include carbon dioxide
  • Self-propelling formulations may also be employed wherein an active compound is dispensed in the form of droplets of solution or suspension.
  • Such self-propelling formulations are analogous to those known in the art and may be prepared by established procedures. Suitably they are presented in a container provided with either a manually-operable or automatically functioning valve having the desired spray characteristics; advantageously the valve is of a metered type delivering a fixed volume, for example, 25 to 100 microlitres, upon each operation thereof.
  • an active compound may be in the form of a solution or suspension for use in an atomizer or nebuliser whereby an accelerated airstream or ultrasonic agitation is employed to produce a fine droplet mist for inhalation.
  • Formulations suitable for nasal administration include preparations generally similar to those described above for pulmonary administration. When dispensed such formulations should desirably have a particle diameter in the range 10 to 200 microns to enable retention in the nasal cavity; this may be achieved by, as appropriate, use of a powder of a suitable particle size or choice of an appropriate valve. Other suitable formulations include coarse powders having a particle diameter in the range 20 to 500 microns, for administration by rapid inhalation through the nasal passage from a container held close up to the nose, and nasal drops comprising 0.2 to 5% w/v of an active compound in aqueous or oily solution or suspension.
  • the pharmaceutical formulations described above may include, an appropriate one or more additional carrier ingredients such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
  • additional carrier ingredients such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
  • Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, 0.1 M and preferably 0.05 M phosphate buffer or 0.8% saline. Additionally, pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as oiive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.
  • Formulations suitable for topical formulation may be provided for example as gels, creams or ointments.
  • Liquid or powder formulations may also be provided which can be sprayed or sprinkled directly onto the site to be treated, e.g. a wound or ulcer.
  • a carrier such as a bandage, gauze, mesh or the like can be impregnated, sprayed or sprinkled with the formulation and then applied to the site to be treated.
  • Therapeutic formulations for veterinary use may conveniently be in either powder or liquid concentrate form.
  • conventional water-soluble excipients such as lactose or sucrose, may be incorporated in the powders to improve their physical properties.
  • suitable powders of this invention comprise 50 to 100% w/w and preferably 60 to 80% w/w of the active ingredient(s) and 0 to 50% w/w and preferably 20 to 40% w/w of conventional veterinary excipients.
  • These powders may either be added to animal feedstuffs, for example by way of an intermediate premix, or diluted in animal drinking water.
  • Liquid concentrates of this invention suitably contain the compound or a derivative or salt thereof and may optionally include an acceptable water-mi scible solvent for veterinary use, for example polyethylene glycol, propylene glycol, glycerol, glycerol formal or such a solvent mixed with up to 30% v/v of ethanol.
  • the liquid concentrates may be administered to the drinking water of animals.
  • a suitable dose of the one or more compounds of the invention may be in the range of about 1 to about 5000 /kg body weight of the subject per day, e.g., 1 , 5, 10, 25, 50, 100, 250, 1000, 2500 or 5000 per day.
  • the compound(s) is a salt, solvate, prodrug or the like
  • the amount administered may be calculated on the basis the parent compound and so the actual weight to be used may be increased proportionately.
  • Transdermal administration may be achieved with the use of impregnated coverings dressings, bandages or the like or via the use of some form of transdermal delivery device.
  • transdermal delivery devices may include, for example, a patch, dressing, bandage or plaster adapted to release a compound or substance through the skin of a patient.
  • a person of skill in the art would be familiar with the materials and techniques which may be used to transdermally deliver a compound or substance and exemplary transdermal delivery devices are provided by GB2185187, US3249109, US3598122, US4144317, US4262003 and US4307717.
  • any of the compounds provided by this invention may be combined with some form of matrix or substrate, such as a non-aqueous polymeric carrier, to render it suitable for use in a bandage, dressing, covering or transdermal delivery system.
  • the compound matrix or substrate mixture may be further strengthened by the use of a woven or knit, non-woven, relatively open mesh fabric, to produce a patch, bandage, plaster or the like which may be reversibly attached to a particular region of a patient's body, in this way, while in contact with a patient's skin, the transdermal delivery device releases the compound or substance through the skin.
  • a weight related disorder may include any disease, condition or syndrome directly and/or indirectly associated with the weight of a subject.
  • the compositions, medicaments and methods described herein may find application in the treatment and/or prevention of obesity and/or diabetes, especially type 2 diabetes - a condition known to be associated with obesity.
  • Other diseases and/or conditions which might be embraced by the term "weight related disorders" include, for example, obesity and being overweight, dyslipidaemia, insulin resistant syndromes, Metabolic Syndrome, steatohepatitis/fatty liver and non-alcoholic fatty liver disease.
  • weight elated disorders may include, for example, hyperglycaemia, glucose intolerance and impaired glucose tolerance, insulin resistance, hyperlipidaemia, hypertriglyceridaemia, hypercholesterolaemia, low HDL levels, high LDL levels and abdominal obesity.
  • weight related disorders may encompass cardiovascular complications resulting as a consequence of conditions such as obesity, diabetes and/or hyperglycaemia; disorders of this type may include endothelial dysfunction, atherosclerosis, hypertension, cardiovascular disease and certain cancer.
  • one embodiment of the invention provides compounds which modulate TsT function, activity and/or expression for use in treating or preventing obesity and/or type 2 diabetes.
  • the primary focus of this invention is the treatment and/or prevention of disorders affecting humans, the invention may also extend to the treatment of the same or similar conditions occurring in other species, in particular mammals such as canine, rodent and/or feline species.
  • the present invention provides a method of diagnosing a weight related disorder, disease, condition or syndrome or a susceptibility and/or predisposition thereto, said method comprising the steps of:
  • detecting a level of the TsT enzyme of TsT expression in said sample might indicate that the subject is suffering from, or predisposed/susceptible to, a weight related disorder.
  • sample for use in the methods described herein may comprise a sample of a biological fluid such as blood, including whole blood or a component or fraction thereof such as, for example, serum or plasma.
  • samples of biological fluid may comprise saliva, sweat and/or semen.
  • samples such as tissue biopsies and/or scrapings may be used.
  • tissue biopsies and/or scrapings may be used.
  • biopsies may comprise cells, for example adipose or hepatocyte cells.
  • a sample may comprise a tissue or gland secretion and washing protocols may be used to obtain samples of fluid secreted into or onto various tissues.
  • TsT protein or TsT nucleic acid i.e. DNA or RNA
  • subjects diagnosed as suffering from a weight related disorder or having a susceptibility or predisposition thereto may yield samples which exhibit modulated and/or aberrant TsT expression, function or activity.
  • the term "aberrant” or “modulated” expression, function and/or activity should be understood to encompass levels expression, function or activity that are either increased and/or decreased relative to the expression, function and/or activity of TsT genes/proteins detected or identified in samples derived from healthy subjects or from subjects of known status (either overweight, suffering from a weight related disorder and/or prone to leanness).
  • all of the diagnostic methods described herein may further comprise the optional step of comparing the results with those obtained from reference or control samples, wherein aberrant or modulated TsT function, expression and/or activity in a sample tested, manifests as a level of TsT expression, function and/or activity which is different from (i.e. higher or lower than) the level of TsT expression, function and/or activity identified in the reference or control sample.
  • TsT enzyme or fragments or portions thereof
  • TsT gene and fragments or portions thereof
  • molecular detection techniques such as PCR, or PCR based protocols, may be used. Such methods may be particularly useful when the user wishes to detect levels of TsT expression, function and/or activity.
  • immunological detection techniques may be used including, for example ELISA and the like. Immunological detection techniques are most useful where the user wishes to probe samples for levels of TsT expression, function and/or activity.
  • PCR based techniques may be used to detect levels of TsT gene expression or gene quantity in a sample.
  • Useful techniques may include, for example, polymerase chain reaction (PCR) using genomic DNA as template or reverse transcriptase (RT)- PCR (see below) based techniques in combination with real-time PCR (otherwise known as quantitative PCR).
  • real time-PCR may be used to determine the level of expression of the TsT genes.
  • RT-PCR may be used to reverse transcribe the relevant mRNA to complementary DNA (cDNA).
  • the reverse transcriptase protocol may use primers designed to specifically amplify an mRNA sequence of interest (in this case TsT gene derived mRNA). Thereafter, PCR may be used to amplify the cDNA generated by reverse transcription. Typically, the cDNA is amplified using primers designed to specifically hybridise with a certain sequence and the nucleotides used for PCR may be labelled with fluorescent or radiolabelled compounds.
  • primers designed to specifically amplify an mRNA sequence of interest in this case TsT gene derived mRNA
  • PCR may be used to amplify the cDNA generated by reverse transcription.
  • the cDNA is amplified using primers designed to specifically hybridise with a certain sequence and the nucleotides used for PCR may be labelled with fluorescent or radiolabelled compounds.
  • the amount of labelled amplified nucleic acid may be determined by monitoring the amount of incorporated labelled nucleotide during the cycling of the PCR.
  • PCR Primer A Laboratory Manual, Second Edition Edited by Carl W. Dieffenbach & Gabriela S. Dveksler: Cold Spring Harbour Laboratory Press and Molecular Cloning: A Laboratory Manual by Joseph Sambrook & David Russell: Cold Spring Harbour Laboratory Press.
  • RNA may be extracted from, for example, a cell using techniques known to the skilled artisan, and subjected to electrophoresis.
  • a nucleic acid probe designed to hybridise (i.e. complementary to) an mRNA sequence of interest - in this case mRNA encoding all or part of the TsT gene, may then be used to detect and quantify the amount of a particular mRNA present in a sample.
  • a level of TsT gene expression may be identified by way of microarray analysis. Such a method would involve the use of a DNA or RNA microarray comprising nucleic acid derived the TsT gene - perhaps a representation of the human genome.
  • a level of TsT gene expression one of skill in the art may contact a sample, optionally processed to extract nucleic acid present therein, with a microarray comprising TsT nucleic acid at one or more defined loci.
  • nucleic acid preferably mRNA may be extracted from the sample and subjected it to an amplification protocol such as, RT-PCR to generate cDNA.
  • the amplified TsT cDNA may be subjected to a further amplification step, optionally in the presence of labelled nucleotides (as described above). Thereafter, the optionally labelled amplified cDNA may be contacted with the microarray under conditions which permit binding with the DNA of the microarray. In this way, it may be possible to identify a level of TsT gem expression.
  • a sample may be subjected to a protocol which utilises an enzyme based detection process.
  • the sample might be contacted with a system comprising a known TsT substrate, where presence of functional or active TsT in the sample causes metabolism of the substrate.
  • detection of the reaction metabolites might serve to indicate a level of TsT present in the sample.
  • immunological detection techniques such as, for example, may be used to identify aberrant levels of TsT function, expression and/or activity in samples.
  • immunological detection techniques such as enzyme- linked immunosorbent assays/spot (ELISA/ELISPOT), dot blot and/or Western blot techniques may also be used.
  • Immunological detection techniques may require the use of a substrate to which an antibody and/or antigen may be bound, conjugated or otherwise immobilised.
  • the substrates provided by this invention may comprise a TsT enzyme or TsT protein (for example a portion or fragment of the whole TsT enzyme) bound, conjugated and/or immobilised thereto.
  • the substrate may comprise an agent, for example an antibody, capable of binding a TsT protein - substrates of this type may be used in capture type immunological detection methods.
  • Suitable substrates may comprise, for example, glass, nitrocellulose, paper, agarose and/or plastic.
  • a substrate which comprises, for example, a plastic material, may take the form of a microtitre plate.
  • references to agents capable of binding a TsT protein may include antibodies and in particular polyclonal and/or monoclonal antibodies. Techniques used to generate antibodies are well known in the art and may involve the use of TsT proteins in animal immunisation protocols or as a basis for the generation of hybridomas. Further information on the preparation and use of polyclonal and/or monoclonal antibodies may be obtained from Using Antibodies: A Laboratory Manual by Harlow & Lane (CSHLP: 1 99) and Antibodies: A Laboratory Manual by Harlow & Lane (CSHLP: 1988) - both of which are incorporated herein by reference.
  • Immunological detection techniques such as, ELISA, may be classed as
  • an indirect/capture ELISA may exploit the use of a substrate coated with an agent capable of binding a TsT protein whereas a direct ELISA may utilise substrates with a TsT protein bound, conjugated or immobilised thereto.
  • An ELISA may involve contacting a sample with a substrate (such as a substrate described above) under conditions which permit binding between proteins (for example TsT proteins) present in the sample and the substrate and/or substances bound or immobilised to the substrate.
  • immunological detection techniques such as ELISA, may utilise blocking steps to reduce or prevent non-specific binding.
  • An ELISA may comprise the further step of contacting the substrate with a secondary antibody having specificity or affinity for TsT protein bound thereto (either directly or via an antibody which is itself immobilised, bound or conjugated to the substrate and which has affinity for the TsT protein).
  • Secondary antibodies for use in this invention may be rodent or ruminant antibodies (polyclonal or monoclonal) specific to particular forms of antibody present within the sample being tested.
  • secondary antibodies may be conjugated to moieties which permit them to be detected - such moieties being referred to hereinafter as detectable moieties.
  • a secondary antibody may be conjugated to an enzyme capable of being detected via a colourmetric/chemiluminescent reaction.
  • conjugated enzymes may include but are not limited to Horse radish Peroxidase (H P) and alkaline phosphatise (AlkP).
  • the secondary antibodies may be conjugated to a fluorescent molecule such as, for example, a fluorophore, such as FITC, rhodamine or Texas Red.
  • fluorophore such as FITC, rhodamine or Texas Red.
  • Other types of detectable moiety include radiolabelled moieties.
  • the amount of secondary antibody detected as bound to the substrate may be representative of the amount of TsT protein present in the sample being tested.
  • a substrate (optionally comprising an agent capable of binding a TsT protein) may be contacted with a sample to be tested. Any TsT protein bound to the substrate (perhaps via an agent capable of binding a TsT protein) may be detected with the use of a further agent capable of binding a TsT protein - referred to hereinafter as a primary antibody.
  • the primary binding agent may be an antibody, optionally conjugated to a detectable moiety as described above.
  • the methods for detecting TsT proteins and/or TsT genes or levels of expression, function and/or activity thereof may take the form of an immunochromatographic test - otherwise known as a "dip-stick” or "pen” tests, where a substrate, or portion thereof, is contacted with a sample to be tested. Thereafter, the test sample flows through and/or along a substrate (perhaps guided by microfluidic channels) under capillary action and is brought into contact with an agent or agents which enables detection of any TsT/TsT gene/proteins or fragments thereof in the sample.
  • Such tests can offer rapid result and exemplary devices may include those known as lateral flow devices.
  • test line The results of a dip-stick or lateral flow test may be revealed in a "test line" where, for example, a change in appearance of the test line may indicate a positive result (i.e. presence of a TsT nucleic acid or TsT protein).
  • Agents capable of effecting detection of TsT genes or TsT proteins in a sample may include particles such as, for example latex or gold particles optionally coated with compounds capable of binding the target analyte (namely TsT of a TsT gene/nucleic acid) in a sample.
  • particles such as, for example latex or gold particles optionally coated with compounds capable of binding the target analyte (namely TsT of a TsT gene/nucleic acid) in a sample.
  • Other forms of particle such as, for example, fluorescent and/or magnetic particles may also be used.
  • a Western blot may involve subjecting a sample to electrophoresis so as to separate or resolve the components, for example the proteinaceous components, of the sample.
  • electrophoresis techniques may be used to separate proteins purified from recombinant (perhaps microbial) systems. The resolved components/proteins may then be transferred to a substrate, such as nitrocellulose.
  • the substrate for example nitrocellulose substrate
  • the substrate to which the resolved components and/or proteins have been transferred, may be contacted with an agent capable of binding TsT proteins under conditions which permit binding between any TsT protein in the sample (or transferred to the substrate) and the agents capable of binding the TsT protein.
  • the agents capable of binding the TsT protein may be conjugated to a detectable moiety.
  • immunological techniques which may be used to identify a level of TsT protein in a sample include, for example, immunohistochemistry wherein binding agents, such as labelled antibodies capable of binding TsT, are contacted with a sample such as those described above, under conditions which permit binding between any TsT protein present in the sample and the binding agent.
  • binding agents such as labelled antibodies capable of binding TsT
  • the sample is treated with, for example a detergent such as Triton XI 00.
  • a detergent such as Triton XI 00.
  • the level of TsT protein identified in a sample may be compared with a level identified in a control or reference sample.
  • the present invention provides a transgenic animal genetically modified to aberrantly express the TsT gene.
  • Such animals may be modified to exhibit markedly reduced (i.e. no) TsT gene expression or, in other cases, substantially increased TsT expression.
  • transgenic animals provided by this invention are particularly useful in the study of weight related disorders.
  • Such animals or indeed cells derived therefrom may be used as the basis of methods for testing agents for potential use in the treatment of a weight related disorder.
  • a test agent By contacting a transgenic animal, or cell derived therefrom with a test agent and thereafter monitoring the level of TsT (gene/protein) expression, function and/or activity, it may be possible to screen libraries of test agents for those for use in the treatment or prevention of weight related disorders.
  • TsT gene/protein
  • kits comprising reagents and compositions suitable for diagnosing, detecting or evaluating levels of TsT in subjects.
  • Kits according to this invention may be used to identify and/or detect aberrant or modulated levels of TsT protein/gene expression, function or activity in samples.
  • the kits may comprise substrates having TsT proteins or agents capable of binding TsT proteins, bound thereto.
  • the kits may comprise agents capable of binding TsT proteins - particularly where the kit is to be used to identify levels TsT protein in samples.
  • the kit may comprise polyclonal antibodies or monoclonal antibodies which exhibit specificity and/or selectivity for one or more TsT proteins.
  • Antibodies for inclusion in the kits provided by this invention may be conjugated to detectable moieties.
  • Kits for use in detecting the expression of the TsT gene may comprise one or more oligonucleotides/primers for detecting/amplifying/probing samples (particularly samples comprising nucleic acid for TsT protein) for TsT encoding sequences.
  • the kits may also comprise other reagents to facilitate, for example, sequencing, PCR and/or RFLP analysis. All kits described herein may further comprise instructions for use.
  • FIG. 2 The effects of adipose-specific Tst overexpression on weight gain and diabetes in mice, a) Quantification of mRNA (upper panel) and protein levels (lower panel) in adiponectin promoter-driven Tst transgenic mice (Ad-Tst).
  • FIG. 3 TsT levels in adipose tissue of obese rodents and humans, a) Tst mRNA levels in control diet (black bar) or 18 week high fat-fed (HF) C57BL/6J (6J) mice (white bar), b) Tst mRNA levels in 10 week old C57BI/6J (black bar) or genetically obese leptin deficient (Lepob: C51&L16l' epob/oh ) mice (grey bar), c) Tst protein levels in SC adipose tissue of 6J, HF fed 6J (6JHF) and in Lep o mice.
  • TST mRNA is expression throughout differentiation of clonal human adipocytes (SGBS cells), e) Effects of the Tst activator thiosulfate (on adiponectin release from mature human SGBS adipocytes.
  • FIG. 5 The Tst activator thiosulfate (sodium thiosulfate, STS) ameliorates weight gain and diabetes in chronically high fat fed (HF) mice.
  • Tst substrate activator thiosulfate is anti-diabetic.
  • Thiosulfate ameliorated A. polydipsia (excessive fluid intake) and B. polyuria (excessive urine production) without affecting C. food/calorie intake or D. final body weight or E. final organ weight, F.
  • ITT insulin sensitisation
  • HbAlc glycosylated haemoglobin
  • Key grey bars, control normal mice with blood glucose ⁇ 6mM, white bars, control (water-treated) Lepr mice, black bars, thiosulfate-treated mice.
  • Adipose-specific TsT overexpressing mice The mouse 0.9kb TsT cDNA was excised from the MCS of EX-Mm05875-Lv08 lentiviral expression vector (Genecopoeia, Open Biosystems) using EcoRl and Nhel.
  • Adipro, ref upstream adiponectin promoter
  • Adipro-5'TsT3'- 3'UTR was identifed using restriction digestion and this clone was maxi-prepped and purified.
  • the Adipro-TsT was excised from the plasmid backbone using Pvul and SacII digestion to give a ⁇ 8kbp transgene fragment that was purified by agarose gel electrophoresis and then microinjected into the pronuclei of fertilized oocytes from C57BL/6N mice by standard techniques (Turku Center for Disease Modelling, Department of Physiology, Institute of Biomedicine, University of Turku, Finland). Offspring were screened by PCR on genomic DNA extracted from tail tips using Adipro-TsT specific primers that amplified a unique transgenic band. 4 male and 1 female founders were identified and transferred to the Biomedical facility, University of Edinburgh.
  • mice were killed within 1 minute of disturbing the home cage by cervical dislocation, to avoid stress-induced changes in metabolic parameters.
  • Blood was collected in EDTA coated tubes (Sarstedt, Numbrecht, Germany).
  • Plasma insulin was measured by ELISA (Crystalchem, Downers Grove, IL, USA), glucose by (Infinity reagent, Sigma, Dorset, Uk) and free fatty acids (Wako Diagnostics, Neuss, Germany) levels (FFA) were measured with a colorimetric method.
  • Adiponectin high molecular weight was measure by ELISA (Alpco, Salem, US). Liver (L), muscle (quadriceps, M), kidney ( ), and epididymal (E), subcutaneous (S), and mesenteric (M) adipose tissues were collected, weighed and stored at -80°C.
  • mice were fasted for 6 hours at 8am then injected with 2mg/g D-glucose (25% stock solution in saline) intraperitoneally. Blood was sampled into EDTA-coated tubes at 0, 2, 5, 10, 15, 30, 60, and 120min intervals after glucose bolus. Glucose levels were determined immediately with a OneTouch glucose meter (Lifescan, High Wicombe, UK) and NEFA and insulin levels were determined as above.
  • RNAs were processed through standard Affymetrix protocols and imported into BioConductor for background subtraction and normalization with the Robust Multichip Average (RMA) algorithm.
  • RMA Robust Multichip Average
  • Differential expression was determined using the Bioconductor Limma tool and the Benjamini and Hochberg FDR method.
  • Annotation data for the genes were obtained from NetAffx.
  • a web accessible front-end query tool generated normalised expression, fold-changes and p-values. Clustering and pathways analyses were carried out using WebGestalt (http: ⁇ ioinfo.vanderbilt.edu/webgestalt, Vanderbilt University, USA), David and Genego.
  • Snap-shot microarray Our first experiment was designed to look across a panel of tissues of the F and L mice including 3 white adipose tissue depots, muscle, liver and kidney for broad and large qualitative fold-changes in gene expression. Tissues were pooled from 3 chow fed mice of each line. RNA was hybridised to Affymetrix Genechip 2.0 arrays as described above. We confirmed the previously described differences in gene expression (Morton et al., 2005) as validatory transcriptome 'landmarks' for the qualitative microarray data. The snap-shot approach allowed us to 1. Assess which genes were grossly different between the Fat and Lean lines in all tissues tested. 2. Provide information on which genes were divergently expressed selectively across all white adipose depots. 3.
  • Bioinformatics analysis of microarray data 1.
  • Experiment 1 looked at qualitative fold changes in gene expression between the lines in the 3 WAT depots (subcutaneous (S), epididymal (E) and mesenteric (M), liver (L), muscle (M) and kidney ( ).
  • We set the fold-difference threshold for changes of interest to > ⁇ 1.5 (negative numbers, denotes genes that are pregulated in Lean, positive numbers '+' denotes upregulated in Fat lines, respectively).
  • We set the fold change within B, L, M or K to be within ⁇ 1.5.
  • the 3T3-L1 preadipocyte cell line (Green and Meuth 1974) was cultured in Dulbecco's modified Eagle medium (DMEM) (Cambrex, Venders, Belgium) supplemented with 10% new bora calf serum (NCS), 2mM L-glutamine, penicillin (50U ml) and streptomycin (50 ug/ml) (Invitrogen, Paisley, UK) at 37°C in humidified atmosphere with 5% C02.
  • DMEM Dulbecco's modified Eagle medium
  • NCS new bora calf serum
  • 2mM L-glutamine penicillin
  • streptomycin 50 ug/ml
  • Confluent 3T3-L1 cells were differentiated by replacing NCS with 10% FBS and supplementing with 0.5mM isobutylmethylxanthine (IBMX), 0.25 ⁇ dexamethasone (Dex), ⁇ g ml insulin and ⁇ Rosiglitazone.
  • Adipocyte TsT knock down in differentiating preadipocytes was performed using siRNA-mediated transfection with the DeliverX Plus kit (Panomics, Freemont, CA, USA) with lOnM each of 3 different inventoried TsT siRNAs (Applied Biosystems: s75542, s202323, and s75543, of which the latter was the most effective in our system).
  • Gapdh (ID 430849) and a non-specific scrambled siRNA (ID 4390843) were used as controls. Knockdown was initiated at day 3 post differentiation and cells remained exposed to the reagent for 72 hours before continuing to day 8 for oil red O lipid accumulation analysis.
  • TsT knockdown was improved efficiency of TsT knockdown in mature fat cells.
  • Lentiviral particles were produced using a shTsTmir or a control scrambled shRNAmir by transfection of HEK293T cells with packaging vectors according to instructions (Open Biosystems).
  • the medium was replaced and the excitation(579nm)- emission(599nm) was quantified using an Ml 000 fluorescence reader and analyzed using Magellan software (Tecan Uk Ltd, Reading, UK).
  • NEFA release was measured using the Wako NEFA kit (Wako Diagnostics, VA, US) and adiponectin secretion was measured at 1 :75 dilution with an EL1SA (Quantikine, R&D Systems, UK).
  • 3T3- Ll cell lipid accumulation was measured at day 8 of differentiation following siRNA mediated knockdown from day 3 to day 6.
  • SGBS Human Simpson-Golabi-Behmel syndrome
  • differentiation medium DMEM/F12 supplemented with 10% heat -inactivated FBS, penicillin/streptomycin (50 U/ml and 50 pg/ml, respectively), 33 ⁇ biotin, 17 ⁇ pantothenic acid, 0.5mM IBMX, 0.25 ⁇ DEX, 20nM insulin, 2 ⁇ rosiglitazone, O.Olmg/ml transferrin, 0.1 ⁇ Cortisol and 200pM triiodothyronine (T3). Cells were maintained in this for 4 days with the medium changed every 48 hours, after which the differentiation medium (as above) was used but without rosiglitazone.
  • differentiation medium DMEM/F12 supplemented with 10% heat -inactivated FBS, penicillin/streptomycin (50 U/ml and 50 pg/ml, respectively
  • T3 triiodothyronine
  • cDNA was synthesised from 2 g RNA using Reverse Transcription system (Promega, Southampton, UK) with oligo(dT) primer, according to the manufacturer's instructions.
  • Realtime PCR was performed on cDNA made from tissue or cell RNA as described above using a Roche Lightcycler 480 mastermix (Roche Diagnostic Ltd, West Wales, UK) and primer/probe sets from Applied Biosystems (Foster City, CA) or TaqMan® Gene expression Assays (Applera, Cheshire, UK).
  • Probes used in this study were mouse TsT: Mm00726109_mL Gapdh (internal control): Mm99999915_gl and TBP (internal control): Mm0000446973_ml.
  • Human TsT was measured using Hs00361812_ml in SGBS cells and in human adipose.
  • Tst mRNA and protein was elevated in adipose tissue of a genetically lean mouse strain where there is good evidence it is causal for a degree of their leanness. Conversely, Tst was low in adipose tissue from a number of obese mouse strains and in human fat from obese patients. We hypothesised that high Tst levels were beneficial for adipose tissue function and promoted leanness, which we showed in a transgenic animal overexpressing Tst under and adipose-specific promoter.
  • Tst activators represent a novel medicament for the treatment of weight related disorders.
  • thiosulfate is nontoxic and has been used clinically to effectively treat a number of unrelated disorders from cyanide detoxification (Baskin et al., 1999) to prevention of serious tissue calcium deposition (including coronary artery disease) in humans (Hayden and Goldsmith 2010, Adirekkiat et al., 2010) and rats (Pasch et al., 2008) and heart failure in mice (Sen et al., 2008), we suggest in the first instance that this compound could be re-positioned for the treatment of weight-related disorders such as obesity and type 2 diabetes.
  • Assays were carried out in 96-well microplates in total volume of ⁇ . Assays contained the following components:
  • Microplates were incubated at room temperature for 5 minutes and KCN (SOmM) added to each well. Following a further 5 minute incubation, 67 ⁇ 1 of solution was removed and transferred to a new mcroplate. 7 ⁇ 1 formaldehyde and 30 ⁇ 1 Fe(N0 ) 3 were then added. The microplate was centrifuged for 5 minutes at 4000rpm and the contents transferred to a new microplate. Absorbance at 460nM was measured in a tunable microplate reader.
  • KCN SOmM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne la découverte selon laquelle l'expression du gène codant pour l'enzyme, thiosulfate sulfurtransférase et l'activité ou fonction de l'enzyme TsT elle-même, sont élevées dans les tissus d'animaux maigres. Par conséquent, l'invention concerne des compositions, méthodes et médicaments pour traiter ou prévenir des troubles liés au poids ainsi que des méthodes et des dosages pour le diagnostic ou la détection d'un trouble lié au poids et/ou une prédisposition/vulnérabilité à un tel trouble.
PCT/GB2012/000108 2011-02-02 2012-02-02 Troubles liés au poids Ceased WO2012104589A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1101793.6 2011-02-02
GBGB1101793.6A GB201101793D0 (en) 2011-02-02 2011-02-02 Weight related disorders

Publications (1)

Publication Number Publication Date
WO2012104589A1 true WO2012104589A1 (fr) 2012-08-09

Family

ID=43824992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/000108 Ceased WO2012104589A1 (fr) 2011-02-02 2012-02-02 Troubles liés au poids

Country Status (2)

Country Link
GB (1) GB201101793D0 (fr)
WO (1) WO2012104589A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246916B2 (en) 2019-05-31 2022-02-15 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249109A (en) 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4262003A (en) 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4378364A (en) * 1970-05-05 1983-03-29 Grassetti Davide R Postoperative treatment of carcinoma patients
GB2185187A (en) 1986-01-13 1987-07-15 Alza Corp Transdermal drug delivery device
US5601806A (en) 1991-12-27 1997-02-11 Sogo Pharmaceutical Company Limited Methods for scavenging active oxygen compounds and preventing damage from ultra violet B rays using taurine analogues
WO2002002190A2 (fr) * 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention et traitement de maladies degeneratives par le glutathion et des enzymes de detoxification de phase ii

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249109A (en) 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122B1 (fr) 1969-04-01 1982-11-23
US4378364A (en) * 1970-05-05 1983-03-29 Grassetti Davide R Postoperative treatment of carcinoma patients
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4262003A (en) 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
GB2185187A (en) 1986-01-13 1987-07-15 Alza Corp Transdermal drug delivery device
US5601806A (en) 1991-12-27 1997-02-11 Sogo Pharmaceutical Company Limited Methods for scavenging active oxygen compounds and preventing damage from ultra violet B rays using taurine analogues
WO2002002190A2 (fr) * 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention et traitement de maladies degeneratives par le glutathion et des enzymes de detoxification de phase ii

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"PCR Primer: A Laboratory Manual", COLD SPRING HARBOUR LABORATORY PRESS
ADIREKKIAT S; SUMETHKUL V; INGSATHIT A; DOMRONGKITCHAIPORN S; PHAKDEEKITCHAROEN B; KANTACHUVESIRI S; KITIYAKARA C; KLYPRAYONG P; D: "Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients", NEPHROL DIAL TRANSPLANT., vol. 25, no. 6, June 2010 (2010-06-01), pages 1923 - 9, XP055263994, DOI: doi:10.1093/ndt/gfp755
BASKIN SI; PORTER DW; ROCKWOOD GA; ROMANO JA JR; PATEL HC; KISER RC; COOK CM; TEMAY AL JR: "In vitro and in vivo comparison of sulfur donors as antidotes to acute cyanide intoxication", J APPL TOXICOL., vol. 19, no. 3, May 1999 (1999-05-01), pages 173 - 83
BRODERICK KATE E ET AL: "Cyanide produced by human isolates of Pseudomonas aeruginosa contributes to lethality in Drosophila melanogaster", JOURNAL OF INFECTIOUS DISEASES, vol. 197, no. 3, February 2008 (2008-02-01), pages 457 - 464, XP002675216, ISSN: 0022-1899 *
BÜNGER L; FORSTING J; MCDONALD KL; HORVAT S; DUNCAN J; HOCHSCHEID S; BAILE CA; HILL WG; SPEAKMAN JR: "Long-term divergent selection on fatness in mice indicates a regulation system independent of leptin production and reception", FASEB J., vol. 17, 2003, pages 85 - 7
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 January 1955 (1955-01-01), OKAMOTO, KOZO ET AL: "Experimental pathology of diabetes mellitus. II. (B). Prevention of experimental diabetes mellitus by some chemical substances", XP002675214, retrieved from STN Database accession no. 1955:86045 *
HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, CSHLP
HARLOW; LANE: "Antibodies: A Laboratory Manual", CSHLP
HARLOW; LANE: "Using Antibodies: A Laboratory Manual", 1999, CSHLP
HAYDEN MELVIN R ET AL: "Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate", CARDIOVASCULAR DIABETOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 4, no. 1, 18 March 2005 (2005-03-18), pages 4, XP021007163, ISSN: 1475-2840, DOI: 10.1186/1475-2840-4-4 *
HAYDEN MR; GOLDSMITH DJ: "Sodium thiosulfate: new hope for the treatment of calciphylaxis", SEMIN DIAL., vol. 23, no. 3, May 2010 (2010-05-01), pages 258 - 62
HORVAT S; BUNGER L; FALCONER VM; MACKAY P; LAW A; BULFIELD G; KEIGHTLEY PD: "Mapping of obesity QTLs in a cross between mouse lines divergently selected on fat content", MAMM GENOME., vol. 11, no. 1, 2000, pages 2 - 7
JOSEPH SAMBROOK; DAVID RUSSELL: "Molecular Cloning: A Laboratory Manual", COLD SPRING HARBOUR LABORATORY PRESS
LUO GX; HOROWITZ PM: "The sulfurtransferase activity and structure of rhodanese are affected by site-directed replacement of Arg-186 or Lys-249", J BIOL CHEM., vol. 269, no. 11, 18 March 1994 (1994-03-18), pages 8220 - 5
MORTON NM; DENSMORE V; WAMIL M; RAMAGE L; NICHOL K; BÜNGER L; SECKL JR; KENYON CJ: "A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action", DIABETES, vol. 54, no. 12, 2005, pages 3371 - 8
OLENA MOROZOVAA; MARCO A. MARRA: "Applications of next-generation sequencing technologies in functional genomics", GENOMICS, vol. 92, no. 5, November 2008 (2008-11-01), pages 255 - 264, XP025535324, DOI: doi:10.1016/j.ygeno.2008.07.001
PASCH A; SCHAFFNER T; HUYNH-DO U; FREY BM; FREY FJ; FARESE S: "Sodium thiosulfate prevents vascular calcifications in uremic rats", KIDNEY INT., vol. 74, no. 11, 2008, pages 1444 - 53
PETRIKOVICS I ET AL: "Encapsulation of Rhodanese and Organic Thiosulfonates by Mouse Erythrocytes", FUNDAMENTAL AND APPLIED TOXICOLOGY, SOCIETY OF TOXICOLOGY, AKRON, OH, US, vol. 23, no. 1, 1 July 1994 (1994-07-01), pages 70 - 75, XP024875763, ISSN: 0272-0590, [retrieved on 19940701], DOI: 10.1006/FAAT.1994.1080 *
POLO CESAR F ET AL: "STZ-induced diabetes in mice and heme pathway enzymes: Effect of allylisopropylacetamide and alpha-tocopherol", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 95, no. 3, 1995, pages 327 - 334, XP002675215, ISSN: 0009-2797 *
RONAGHI: "Pyrosequencing sheds light on DNA sequencing", GENOME RESEARCH, vol. 11, pages 3 - 11, XP000980886, DOI: doi:10.1101/gr.11.1.3
SEN U; VACEK TP; HUGHES WM; KUMAR M; MOSHAL KS; TYAGI N; METREVELI N; HAYDEN MR; TYAGI SC: "Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation", PHARMACOLOGY, vol. 82, no. 3, 2008, pages 201 - 13
SIMONCIC M; HORVAT S; STEVENSON PL; BUNGER L; HOLMES MC; KENYON CJ; SPEAKMAN JR; MORTON NM, BEHAV GENET., vol. 38, no. 3, May 2008 (2008-05-01), pages 292 - 300
STYLIANOU IM; CLINTON M; KEIGHTLEY PD; PRITCHARD C; TYMOWSKA-LALANNE Z; BÜNGER L; HORVAT S: "Microarray gene expression analysis of the Fob3b obesity QTL identifies positional candidate gene Sqle and perturbed cholesterol and glycolysis pathways", PHYSIOL GENOMICS, vol. 20, no. 3, 10 February 2005 (2005-02-10), pages 224 - 32

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246916B2 (en) 2019-05-31 2022-02-15 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins

Also Published As

Publication number Publication date
GB201101793D0 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
Chung et al. Conjugated linoleic acid promotes human adipocyte insulin resistance through NFκB-dependent cytokine production
Tavernier et al. β3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human β3-adrenergic receptor
Gong et al. Claudin-14 underlies Ca++-sensing receptor–mediated Ca++ metabolism via NFAT-microRNA–based mechanisms
JP6378113B2 (ja) ヒト骨格筋における褐色脂肪細胞前駆体
Liu et al. Sirt1 mediates the effect of the heme oxygenase inducer, cobalt protoporphyrin, on ameliorating liver metabolic damage caused by a high-fat diet
Valverde et al. Insulin signaling in insulin receptor substrate (IRS)-1-deficient brown adipocytes: requirement of IRS-1 for lipid synthesis.
MX2012009318A (es) Metodos y compuestos para el crecimiento muscular.
JPWO2011145723A1 (ja) メタボリックシンドロームの予防又は治療方法
KR20220041896A (ko) Klf 유도 심근생성
HK1202309A1 (en) Brown adipocyte progenitors in human skeletal muscle
Yan et al. CGRP attenuates pulmonary vascular remodeling by inhibiting the cGAS-STING-NFκB pathway in pulmonary arterial hypertension
Bourgeois et al. The ammonia transporter RhCG modulates urinary acidification by interacting with the vacuolar proton-ATPases in renal intercalated cells
US20200199575A1 (en) Role of exosomes, extracellular vesicles, in the regulation of metabolic homeostasis
Yasuoka et al. CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis
Li et al. A role for nuclear factor interleukin-3 (NFIL3), a critical transcriptional repressor, in down-regulation of periovulatory gene expression
Xu et al. Effects of diacylglycerol O-acyltransferase 1 (DGAT1) on endoplasmic reticulum stress and inflammatory responses in adipose tissue of ketotic dairy cows
Sandhofer et al. Beta receptor isoforms are not essential for thyroid hormone-dependent acceleration of PCP-2 and myelin basic protein gene expression in the developing brains of neonatal mice
Gao et al. Nuclear factor I‐C expression pattern in developing teeth and its important role in odontogenic differentiation of human molar stem cells from the apical papilla
US20140378388A1 (en) Treatment of uterine leiomyomata
Morari et al. The role of proliferator-activated receptor γ coactivator–1α in the fatty-acid–dependent transcriptional control of interleukin-10 in hepatic cells of rodents
Villano et al. Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice
WO2012104589A1 (fr) Troubles liés au poids
CN116762010A (zh) 用于选择高质量干细胞的标记物，以及使用其选择高质量干细胞的方法
KR20200018508A (ko) 프로스타글란딘 E-의존적 종양의 계층화에 대한 바이오마커로서 MiRNA-574-5p
KR20100096010A (ko) Ｄｒｇ2 유전자의 신규한 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12706077

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12706077

Country of ref document: EP

Kind code of ref document: A1